Heart Failure Experts Agree: HFmrEF Should Not Be Ignored

Why It Matters

Recognizing HFmrEF as a distinct, high‑risk group prompts more aggressive treatment, potentially reducing hospitalizations and slowing disease progression. Aligning therapy with HFrEF standards could improve outcomes for a sizable patient segment.

Key Takeaways

• HFmrEF affects up to one‑quarter of all heart‑failure patients worldwide
• HFSA recommends applying HFrEF guideline‑directed medical therapy to HFmrEF
• Patients with HFmrEF often progress to reduced ejection fraction over time
• Management should consider remodeling, afterload, ischemic burden, and comorbidities
• New HFSA statement aims to close care gap and guide research

Pulse Analysis

The emergence of HFmrEF as a recognized heart‑failure phenotype reflects a shift in cardiology toward more nuanced patient stratification. Historically labeled a "gray zone," HFmrEF patients share many risk factors with reduced‑ejection‑fraction heart failure, including ischemic disease, atrial fibrillation, and diabetes. By quantifying its prevalence—roughly one in four heart‑failure cases—the HFSA statement underscores the urgency of addressing this cohort, especially as many patients transition to more severe disease states.

Guideline‑directed medical therapy (GDMT) that has proven mortality and morbidity benefits in HFrEF now forms the backbone of the HFSA recommendation for HFmrEF. This includes ACE inhibitors, ARBs, ARNIs, beta‑blockers, and mineralocorticoid receptor antagonists, tailored to individual comorbidities and tolerability. The statement also expands the diagnostic lens beyond ejection fraction, urging clinicians to evaluate ventricular remodeling, afterload, and ischemic burden. Such a comprehensive approach aims to personalize treatment, mitigate progression, and reduce costly hospital admissions.

Looking ahead, the HFSA’s call for targeted research could catalyze clinical trials specifically designed for the mildly reduced ejection fraction group. Funding agencies and pharmaceutical firms may prioritize studies that test novel agents or combination therapies in HFmrEF, filling a long‑standing evidence gap. For health systems, adopting the new guidance could improve quality metrics and align reimbursement models with best‑practice care, ultimately delivering better outcomes for a sizable and previously underserved patient population.